Soligenix (SNGX) Competitors $2.10 +0.04 (+1.94%) Closing price 04:00 PM EasternExtended Trading$2.06 -0.04 (-1.90%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. QTTB, GRCE, LSB, JATT, RLYB, ANVS, SNYR, CDIO, CVM, and LSTAShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Q32 Bio (QTTB), Grace Therapeutics (GRCE), Lakeshore Biopharma (LSB), JATT Acquisition (JATT), Rallybio (RLYB), Annovis Bio (ANVS), Synergy CHC Corp. (Uplisting) (SNYR), Cardio Diagnostics (CDIO), CEL-SCI (CVM), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Q32 Bio Grace Therapeutics Lakeshore Biopharma JATT Acquisition Rallybio Annovis Bio Synergy CHC Corp. (Uplisting) Cardio Diagnostics CEL-SCI Lisata Therapeutics Q32 Bio (NASDAQ:QTTB) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has more volatility and risk, QTTB or SNGX? Q32 Bio has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Do analysts prefer QTTB or SNGX? Q32 Bio currently has a consensus target price of $24.71, indicating a potential upside of 1,065.77%. Given Q32 Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Q32 Bio is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Soligenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in QTTB or SNGX? 31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 16.1% of Q32 Bio shares are owned by company insiders. Comparatively, 2.8% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to QTTB or SNGX? In the previous week, Soligenix had 2 more articles in the media than Q32 Bio. MarketBeat recorded 3 mentions for Soligenix and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.93 beat Soligenix's score of 0.72 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, QTTB or SNGX? Soligenix has higher revenue and earnings than Q32 Bio. Soligenix is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio-$6.65M-3.89-$112.96M-$10.37-0.20Soligenix$840K6.28-$6.14M-$6.11-0.34 Is QTTB or SNGX more profitable? Q32 Bio has a net margin of 0.00% compared to Soligenix's net margin of -1,473.38%. Q32 Bio's return on equity of -146.18% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -146.18% -54.49% Soligenix -1,473.38%-223.29%-74.18% Does the MarketBeat Community believe in QTTB or SNGX? Soligenix received 266 more outperform votes than Q32 Bio when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 63.16% of users gave Q32 Bio an outperform vote. CompanyUnderperformOutperformQ32 BioOutperform Votes1263.16% Underperform Votes736.84% SoligenixOutperform Votes27872.97% Underperform Votes10327.03% SummaryQ32 Bio beats Soligenix on 10 of the 18 factors compared between the two stocks. Remove Ads Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.27M$6.45B$5.29B$7.34BDividend YieldN/A3.24%5.11%4.31%P/E Ratio-0.286.8821.7117.76Price / Sales6.28231.35379.1297.68Price / CashN/A65.6738.1534.64Price / Book0.555.916.433.98Net Income-$6.14M$142.72M$3.21B$247.44M7 Day Performance10.58%7.98%5.23%4.43%1 Month Performance-11.02%-13.91%-9.53%-7.73%1 Year Performance-74.26%-9.98%10.99%1.28% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix1.513 of 5 stars$2.10+1.9%N/A-72.7%$5.27M$840,000.00-0.2820Short Interest ↓QTTBQ32 Bio2.3538 of 5 stars$1.53-6.7%$24.71+1,515.3%-92.6%$18.66M$-6,651,000.00-0.1139News CoverageGRCEGrace Therapeutics1.9494 of 5 stars$1.80-10.0%$12.00+566.7%N/A$18.25MN/A-1.55N/AGap DownLSBLakeshore Biopharma0.6733 of 5 stars$1.95-6.7%N/AN/A$18.15M$672.27M0.00773Upcoming EarningsShort Interest ↑News CoverageGap UpHigh Trading VolumeJATTJATT AcquisitionN/A$1.03-5.1%N/A-63.7%$17.77MN/A0.003High Trading VolumeRLYBRallybio2.421 of 5 stars$0.42-5.6%$9.75+2,194.7%-86.0%$17.68M$636,000.00-0.2740Analyst ForecastGap DownANVSAnnovis Bio1.453 of 5 stars$1.24-5.7%$37.00+2,896.0%-87.5%$17.58MN/A-0.283Gap UpSNYRSynergy CHC Corp. (Uplisting)3.1198 of 5 stars$2.03-11.7%$10.00+392.6%N/A$17.40M$34.83M0.0040Lockup ExpirationNews CoverageGap DownHigh Trading VolumeCDIOCardio Diagnostics2.1301 of 5 stars$0.33+7.1%$2.00+511.2%-63.7%$17.06M$34,890.000.001Short Interest ↑CVMCEL-SCIN/A$0.21-3.5%N/A-83.1%$16.71MN/A-0.4343Analyst ForecastGap UpLSTALisata Therapeutics2.2615 of 5 stars$1.90-4.5%$15.00+689.5%-27.5%$16.38M$1M-0.7630News CoveragePositive News Remove Ads Related Companies and Tools Related Companies Q32 Bio Competitors Grace Therapeutics Competitors Lakeshore Biopharma Competitors JATT Acquisition Competitors Rallybio Competitors Annovis Bio Competitors Synergy CHC Corp. (Uplisting) Competitors Cardio Diagnostics Competitors CEL-SCI Competitors Lisata Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
